PeerVoice Immunology & Infectious Disease Audio

PeerVoice is committed to producing and distributing evidence-based, independently-created medical education in Immunology & Infectious Disease that is designed to positively impact patient care. Activities can either be accredited or non-accredited but are always driven by the learning and practice needs of healthcare professionals. Learn more at: https://peervoice.com.

64 episodes

2mo ago latest

monthly cadence

English language

▶ Play latestRSS feed Website Science Health Fitness Medicine Education

https://c.peervoice.com/podcast/xml/rheumatology_audio.xml

Episodes 64

David Alain Wohl, MD - From Guidelines to Ground Truth: The Reality of Rapid ART in the Real World
2mo ago · 20:43
For the complete activity, including supporting material, please visit https://www.peervoice.com/DMZ860. Presented by David Alain Wohl, MD; and Antonella Castagna, MD. Learning Objectives: Explain the clinical rationale for rapid antiretroviral therapy (ART) in people with HIV; Evaluate evidence on the benefits and limitations of rapid ART in HIV; Formulate practical steps to align rapid ART practices in HIV with both guideline expectations and real-world realities.
Melanie J. Davies, CBE, MBChB, MD, FMedSci / Linong Ji, MD - Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Established Therapies
6mo ago · 21:52
For the complete activity, including supporting material, please visit https://www.peervoice.com/XZR860. Presented by Melanie J. Davies, CBE, MBChB, MD, FMedSci and Linong Ji, MD. Learning Objectives: Describe the importance of optimal cost-effective approaches to the pharmacologic management of type 2 diabetes mellitus (T2DM); Evaluate the role of established medications for T2DM for avoiding potential cardiorenal complications in patients with T2DM; Propose practical approaches to address cost and clinical effectiveness for patients with T2DM.
Yohei Doi, MD, PhD - Know the Risk, Act on Evidence: Strategic Interventions in COVID-19 Care of High-Risk Patients
6mo ago · 28:36
For the complete activity, including supporting material, please visit https://www.peervoice.com/SDW860. Presented by Yohei Doi, MD, PhD and Sarah Jarvis, MBE, FRCGP. Learning Objectives: Differentiate key clinical and demographic factors, including age, comorbidities, and immune status, that define high-risk COVID-19 patient profiles; Propose strategies to improve early identification of high-risk patients for appropriate COVID-19 treatment; Interpret regional epidemiological data from Europe and Asia-Pacific to contextualise risk profiles for diverse patient populations; Apply clinical crite
Colin Russell, PhD / John Watkins, MBBCh, BSc - A Shot in the Arm: Leveraging Combination Vaccines for Global Health Impact
8mo ago · 17:26
Visit https://www.peervoice.com/THS860 to view the entire programme with slides. After completing “Colin Russell, PhD / John Watkins, MBBCh, BSc - A Shot in the Arm: Leveraging Combination Vaccines for Global Health Impact”, participants will be able to: Recognise the evolving epidemiology and overlapping seasonality of COVID-19 and influenza, and understand how these factors impact vaccine strategies - particularly in managing coinfections, waning immunity, and emerging variants; Understand the latest evidence and data on how combination vaccines could simplify immunisation schedules, improve
David Alain Wohl, MD - Inpatient Management of SARS-CoV-2 Infection: Applying Learnings From Real World Evidence to Real World Practice
9mo ago · 38:52
Visit https://www.peervoice.com/PHJ860 to view the entire programme with slides. After completing “David Alain Wohl, MD - Inpatient Management of SARS-CoV-2 Infection: Applying Learnings From Real World Evidence to Real World Practice”, participants will be able to: Discuss current inpatient management guidelines for patients with SARS-CoV-2 infection; Evaluate the impact of emerging SARS-CoV-2 variants on therapeutic efficacy; Assess the data from real-world studies of the potential impact of established treatments on clinical outcomes including long COVID; Evaluate which patients with SARS-C
Nancy Carteron, MD, FACR - Congress Insights Direct From Chicago: The Need-to-Knows on B Cell–Targeting in Sjögren’s Disease
9mo ago · 19:49
Visit https://www.peervoice.com/YZQ860 to view the entire programme with slides. After completing “Nancy Carteron, MD, FACR - Congress Insights Direct From Chicago: The Need-to-Knows on B Cell–Targeting in Sjögren’s Disease”, participants will be able to: Summarise recently presented clinical trial data evaluating novel therapies in the management of patients with Sjögren’s disease; and Analyse recent evidence on B cell–mediated pathophysiological mechanisms in Sjögren’s disease.
Eva Diehl - Wiesenecker, MD - Rare Causes of Abdominal Pain: Differential Diagnosis of Uncommon but Diagnosable Causes in the Emergency Room
11mo ago · 18:36
Visit https://www.peervoice.com/NUF860 to view the entire programme with slides. After completing “Eva Diehl - Wiesenecker, MD - Rare Causes of Abdominal Pain: Differential Diagnosis of Uncommon but Diagnosable Causes in the Emergency Room”, participants will be able to: Discuss the impact of delayed and/or misdiagnosis of a rare cause of abdominal pain on patients and healthcare systems; Recognise the clinical features that would increase suspicion of a rare cause of abdominal pain; and Apply appropriate diagnostic algorithms for patients who present to the emergency room with severe abdomina
Thanai Pongdee, MD - From Diagnosis to Treatment Escalation: Improving Outcomes Across the Patient Journey in Indolent Systemic Mastocytosis
1y ago · 15:54
Visit https://www.peervoice.com/FPN860 to view the entire programme with slides. After completing “Thanai Pongdee, MD - From Diagnosis to Treatment Escalation: Improving Outcomes Across the Patient Journey in Indolent Systemic Mastocytosis”, participants will be able to: Differentiate symptoms of indolent systemic mastocytosis (ISM) from other conditions with cutaneous manifestations; Implement evidence-based practices in the initial diagnosis and management of ISM; Utilize recommended clinical tools for the evaluation of symptoms and quality of life (QoL) in patients with ISM; and Identify pa
Martin Metz, MD - Bringing Chronic Spontaneous Urticaria Under Control: Available and Anticipated Strategies for Escalating Treatment
1y ago · 19:27
Visit https://www.peervoice.com/EAW860 to view the entire programme with slides. After completing “Martin Metz, MD - Bringing Chronic Spontaneous Urticaria Under Control: Available and Anticipated Strategies for Escalating Treatment”, participants will be able to: Recognise unmet needs and burdens experienced by patients living with inadequately controlled chronic spontaneous urticaria (CSU); Provide appropriate, individualised treatment to patients with CSU whose symptoms are inadequately controlled with second-generation H1-antihistamines; and Assess the clinical significance of clinical tri
Howard Trachtman, MD - Pioneering Progress In Focal Segmental Glomerulosclerosis: Time is Ticking To Save The Nephron
1y ago · 20:38
Visit https://www.peervoice.com/BVP860 to view the entire programme with slides. After completing “Howard Trachtman, MD - Pioneering Progress In Focal Segmental Glomerulosclerosis: Time is Ticking To Save The Nephron”, participants will be able to: Identify the current challenges in the diagnosis and management of focal segmental glomerulosclerosis (FSGS); Recognise genetic and socio-environmental factors that contribute to the disproportionate burden of FSGS and end stage kidney disease in Black communities; Describe the pathophysiology of FSGS, including the role of endothelin-1 and angioten
Saiju Jacob, MD, DPhil, FRCP, FAAN - The Value of Disease Control in gMG: The Latest Data Evaluating Patient Needs and Treatment Outcomes as They Emerge From Helsinki
1y ago · 20:45
Visit https://www.peervoice.com/MZY860 to view the entire programme with slides. After completing “Saiju Jacob, MD, DPhil, FRCP, FAAN - The Value of Disease Control in gMG: The Latest Data Evaluating Patient Needs and Treatment Outcomes as They Emerge From Helsinki”, participants will be able to:
Anna Maria Geretti, MD, PhD - Understanding an Individual’s Readiness for Long-Acting Injectable Therapy
1y ago · 20:07
Visit https://www.peervoice.com/ZCC860 to view the entire programme with slides. After completing “Anna Maria Geretti, MD, PhD - Understanding an Individual’s Readiness for Long-Acting Injectable Therapy”, participants will be able to: Describe the eligibility criteria and patient factors that impact whether long-acting injectable antiretroviral therapy (LAI-ART) is a treatment option for an individual with HIV; Explain key information that individuals with HIV need to know about the potential benefits and limitations of LAI-ART in order for them to be able to make informed decisions on their
Thomas Dörner, MD - B-Cell Depletion for Autoimmune Rheumatic Diseases: Expert Perspectives of This Mechanistic Therapeutic Approach in Clinical Context
1y ago · 53:52
Visit https://www.peervoice.com/SDS860 to view the entire programme with slides. After completing “Thomas Dörner, MD - B-Cell Depletion for Autoimmune Rheumatic Diseases: Expert Perspectives of This Mechanistic Therapeutic Approach in Clinical Context”, participants will be able to: Explain the impact of suboptimal treatment of autoimmune rheumatic diseases on patient outcomes; Discuss the mechanistic role of B cells in the pathophysiology of autoimmune rheumatic diseases; Explain why—despite suboptimal results with established B-cell–targeting therapies in autoimmune rheumatic diseases such a
Nicholas J. Silvestri, MD, FAAN - From Established to Emerging Therapies: Expert Perspectives on the Latest Evidence Base on FcRn Inhibitors for gMG
1y ago · 19:04
Visit https://www.peervoice.com/WWE860 to view the entire programme with slides. After completing “Nicholas J. Silvestri, MD, FAAN - From Established to Emerging Therapies: Expert Perspectives on the Latest Evidence Base on FcRn Inhibitors for gMG”, participants will be able to:
Enrico Lopriore, MD, PhD - Are You Managing Pregnant Individuals? Then You Need to Know About Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT)
1y ago · 25:06
Visit https://www.peervoice.com/YZR860 to view the entire programme with slides. After completing “Enrico Lopriore, MD, PhD - Are You Managing Pregnant Individuals? Then You Need to Know About Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT)”, participants will be able to: Explain the pathogenesis of fetal-neonatal alloimmune thrombocytopenia (FNAIT); Identify individuals with pregnancies suspected to be at risk of FNAIT based on risk factors; Discuss prenatal management and the benefits and limitations of maternal intravenous immunoglobulin (IVIg) for pregnancies at risk of FNAIT; Identify
James F. Howard Jr, MD - Beyond FcRn and Complement Inhibitors: Why We Need Novel Treatment Options for Generalized Myasthenia Gravis
1y ago · 19:34
Visit https://www.peervoice.com/DSN860 to view the entire programme with slides. After completing “James F. Howard Jr, MD - Beyond FcRn and Complement Inhibitors: Why We Need Novel Treatment Options for Generalized Myasthenia Gravis”, participants will be able to: Explain how the immunological processes underpinning the pathophysiology of generalised myasthenia gravis (gMG) are targeted by the novel mechanisms of action of emerging therapies; Discuss key characteristics of currently available targeted therapies for gMG with particular reference to potential benefits and limitations; and Evalua
Mariana Castells, MD, PhD - Rare But Highly Significant: Best Practices in Recognizing and Diagnosing Systemic Mastocytosis
1y ago · 19:58
Visit https://www.peervoice.com/JJU860 to view the entire programme with slides. After completing “Mariana Castells, MD, PhD - Rare But Highly Significant: Best Practices in Recognizing and Diagnosing Systemic Mastocytosis”, participants will be able to: Recognize the prevalence, symptoms, and outcomes associated with systemic mastocytosis (SM); Identify patients who should be referred for diagnostic tests to investigate suspected SM; and Identify diagnostic tests used to investigate and identify cases of SM.
Pushpa Narayanaswami, MD, FAAN - Cutting Through the Congress Cacophony on Generalised Myasthenia Gravis: Expert Honing of the Latest Data
1y ago · 58:59
Visit https://www.peervoice.com/HTH860 to view the entire programme with slides. After completing “Pushpa Narayanaswami, MD, FAAN - Cutting Through the Congress Cacophony on Generalised Myasthenia Gravis: Expert Honing of the Latest Data”, participants will be able to: Analyse the evidence and characteristics of next-generation and new formulations of therapies for generalised myasthenia gravis (gMG) and how they differentiate within class; Translate emerging clinical data for approved targeted therapies in the context of current clinical practice for the management of patients with gMG; and E
Onyema Ogbuagu, MD, FACP, FIDSA - Multidrug-Resistant HIV: Evaluating HIV Treatment Strategies as Options Narrow
1y ago · 25:34
Visit https://www.peervoice.com/BQX860 to view the entire programme with slides. After completing “Onyema Ogbuagu, MD, FACP, FIDSA - Multidrug-Resistant HIV: Evaluating HIV Treatment Strategies as Options Narrow”, participants will be able to: Identify patient and disease characteristics that can impact decisions on next treatment steps for individuals living with multidrug-resistant HIV (MDR HIV); and Propose individualised evidence-based treatment strategies to optimise outcomes of individuals living with MDR HIV.
Stephen Jolles, MRCP, FRCPath, PhD - The Many Faces of Primary Immunodeficiencies: Exploring the Plethora of Possibilities Impacting Patient-Integrated Care
1y ago · 1:15:02
Visit https://www.peervoice.com/JGN860 to view the entire programme with slides. After completing “Stephen Jolles, MRCP, FRCPath, PhD - The Many Faces of Primary Immunodeficiencies: Exploring the Plethora of Possibilities Impacting Patient-Integrated Care”, participants will be able to: Recognise the need for an early and accurate diagnosis of primary immunodeficiency diseases (PID); Differentiate between the clinical presentation of infectious and non-infectious manifestations of PID; Use patient factors, clinical features and laboratory testing to facilitate an effective approach to a timely
Frank Siebenhaar, PD / Vito Sabato, MD, PhD - Optimising Outcomes in Indolent Systemic Mastocytosis: A Comprehensive Review of Best Practices Across the Patient Journey
1y ago · 28:35
Visit https://www.peervoice.com/NXY860 to view the entire programme with slides. After completing “Frank Siebenhaar, PD / Vito Sabato, MD, PhD - Optimising Outcomes in Indolent Systemic Mastocytosis: A Comprehensive Review of Best Practices Across the Patient Journey”, participants will be able to: Differentiate the symptoms, causes and outcomes associated with childhood-onset and adult-onset presentations of mastocytosis; Utilise recommended clinical tools for the evaluation of symptoms and quality of life (QoL) in patients with indolent systemic mastocytosis (ISM); and Implement evidence-bas
Sharon Walmsley, MD - If the Drugs Are Working, Why Switch HIV Treatment in People Who Are Virologically Suppressed?
2y ago · 18:55
Visit https://www.peervoice.com/VZX860 to view the entire programme with slides. After completing “Sharon Walmsley, MD - If the Drugs Are Working, Why Switch HIV Treatment in People Who Are Virologically Suppressed?”, participants will be able to: Explain the rationale for switching antiretroviral therapy (ART) regimens in people with virologically suppressed HIV; Assess the clinical and patient-reported outcomes (PRO) data for HIV switch regimens for people with virologically suppressed HIV; and Based on clinical trial populations, evaluate eligibility criteria of people with virologically su
Jane Anderson, FRCP, PhD - Health-Related Quality of Life: What Works Best for People Living With HIV?
2y ago · 46:20
Visit https://www.peervoice.com/FDX860 to view the entire programme with slides. After completing “Jane Anderson, FRCP, PhD - Health-Related Quality of Life: What Works Best for People Living With HIV?”, participants will be able to: Summarise the rationale for integrating patient-reported outcomes (PRO) instruments into routine clinical practice when caring for people living with HIV; Explain how PRO measures (PROM) can be effectively integrated into routine clinical practice; Identify how PRO can inform HIV treatment plans that optimise outcomes; and Propose practical approaches to overcomin
Xenofon Baraliakos, MD, PhD / Philip Helliwell, MD, PhD - Can the Standard of Care Be Elevated in Spondyloarthropathies? Key Learnings From Rheumacensus Initiatives in PsA and axSpA
2y ago · 15:40
Visit https://www.peervoice.com/AFQ860 to view the entire programme with slides. After completing “Xenofon Baraliakos, MD, PhD / Philip Helliwell, MD, PhD - Can the Standard of Care Be Elevated in Spondyloarthropathies? Key Learnings From Rheumacensus Initiatives in PsA and axSpA”, participants will be able to: Describe the rationale, design, and key areas of focus of the Rheumacensus programmes in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA); Identify the overarching calls to action needed to implement a paradigm shift designed to elevate health outcomes in patients with PsA
Milan J. Anadkat, MD - Supporting Patient-Centered Care in Generalized Pustular Psoriasis: Communications Strategies to Improve Shared Decision-Making
2y ago · 33:41
Visit https://www.peervoice.com/HUM860 to view the entire programme with slides. After completing “Milan J. Anadkat, MD - Supporting Patient-Centered Care in Generalized Pustular Psoriasis: Communications Strategies to Improve Shared Decision-Making”, participants will be able to: Describe key information regarding the disease process and course following the diagnosis of generalized pustular psoriasis (GPP); Address common concerns raised by patients with GPP; and Develop appropriate treatment plans with patients for the management of GPP.

Episodes

Reading the feed…

Also on peervoice.com

More Science shows

Arizona Science

azpm.org

510 episodes · 9d ago

WiTcast

witcastthailand.com

357 episodes · 8d ago

Evrim Ağacı ile Bilime Dair Her Şey!

evrimagaci.org

557 episodes · 8d ago

A Moment of Science

prxu.org

1,000 episodes · 9d ago

Groks Science Radio Show and Podcast

ocf.berkeley.edu

1,000 episodes · 11d ago

Ask the Naked Scientists

thenakedscientists.com

802 episodes · 9d ago

PeerVoice Immunology & Infectious Disease Audio

Episodes 64

David Alain Wohl, MD - From Guidelines to Ground Truth: The Reality of Rapid ART in the Real World

Melanie J. Davies, CBE, MBChB, MD, FMedSci / Linong Ji, MD - Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Established Therapies

Yohei Doi, MD, PhD - Know the Risk, Act on Evidence: Strategic Interventions in COVID-19 Care of High-Risk Patients

Colin Russell, PhD / John Watkins, MBBCh, BSc - A Shot in the Arm: Leveraging Combination Vaccines for Global Health Impact

David Alain Wohl, MD - Inpatient Management of SARS-CoV-2 Infection: Applying Learnings From Real World Evidence to Real World Practice

Nancy Carteron, MD, FACR - Congress Insights Direct From Chicago: The Need-to-Knows on B Cell–Targeting in Sjögren’s Disease

Eva Diehl - Wiesenecker, MD - Rare Causes of Abdominal Pain: Differential Diagnosis of Uncommon but Diagnosable Causes in the Emergency Room

Thanai Pongdee, MD - From Diagnosis to Treatment Escalation: Improving Outcomes Across the Patient Journey in Indolent Systemic Mastocytosis

Martin Metz, MD - Bringing Chronic Spontaneous Urticaria Under Control: Available and Anticipated Strategies for Escalating Treatment

Howard Trachtman, MD - Pioneering Progress In Focal Segmental Glomerulosclerosis: Time is Ticking To Save The Nephron

Saiju Jacob, MD, DPhil, FRCP, FAAN - The Value of Disease Control in gMG: The Latest Data Evaluating Patient Needs and Treatment Outcomes as They Emerge From Helsinki

Anna Maria Geretti, MD, PhD - Understanding an Individual’s Readiness for Long-Acting Injectable Therapy

Thomas Dörner, MD - B-Cell Depletion for Autoimmune Rheumatic Diseases: Expert Perspectives of This Mechanistic Therapeutic Approach in Clinical Context

Nicholas J. Silvestri, MD, FAAN - From Established to Emerging Therapies: Expert Perspectives on the Latest Evidence Base on FcRn Inhibitors for gMG

Enrico Lopriore, MD, PhD - Are You Managing Pregnant Individuals? Then You Need to Know About Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT)

James F. Howard Jr, MD - Beyond FcRn and Complement Inhibitors: Why We Need Novel Treatment Options for Generalized Myasthenia Gravis

Mariana Castells, MD, PhD - Rare But Highly Significant: Best Practices in Recognizing and Diagnosing Systemic Mastocytosis

Pushpa Narayanaswami, MD, FAAN - Cutting Through the Congress Cacophony on Generalised Myasthenia Gravis: Expert Honing of the Latest Data

Onyema Ogbuagu, MD, FACP, FIDSA - Multidrug-Resistant HIV: Evaluating HIV Treatment Strategies as Options Narrow

Stephen Jolles, MRCP, FRCPath, PhD - The Many Faces of Primary Immunodeficiencies: Exploring the Plethora of Possibilities Impacting Patient-Integrated Care

Frank Siebenhaar, PD / Vito Sabato, MD, PhD - Optimising Outcomes in Indolent Systemic Mastocytosis: A Comprehensive Review of Best Practices Across the Patient Journey

Sharon Walmsley, MD - If the Drugs Are Working, Why Switch HIV Treatment in People Who Are Virologically Suppressed?

Jane Anderson, FRCP, PhD - Health-Related Quality of Life: What Works Best for People Living With HIV?

Xenofon Baraliakos, MD, PhD / Philip Helliwell, MD, PhD - Can the Standard of Care Be Elevated in Spondyloarthropathies? Key Learnings From Rheumacensus Initiatives in PsA and axSpA

Milan J. Anadkat, MD - Supporting Patient-Centered Care in Generalized Pustular Psoriasis: Communications Strategies to Improve Shared Decision-Making

Episodes

Also on peervoice.com

PeerVoice Internal Medicine Video

PeerVoice Internal Medicine Audio

PeerVoice Clinical Pharmacology Video

PeerVoice Oncology & Haematology Video

PeerVoice Clinical Pharmacology Audio

PeerVoice Oncology & Haematology Audio

More Science shows

Arizona Science

WiTcast

Evrim Ağacı ile Bilime Dair Her Şey!

A Moment of Science

Groks Science Radio Show and Podcast

Ask the Naked Scientists

Episodes 64

David Alain Wohl, MD - From Guidelines to Ground Truth: The Reality of Rapid ART in the Real World

Melanie J. Davies, CBE, MBChB, MD, FMedSci / Linong Ji, MD - Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Established Therapies

Yohei Doi, MD, PhD - Know the Risk, Act on Evidence: Strategic Interventions in COVID-19 Care of High-Risk Patients

Colin Russell, PhD / John Watkins, MBBCh, BSc - A Shot in the Arm: Leveraging Combination Vaccines for Global Health Impact

David Alain Wohl, MD - Inpatient Management of SARS-CoV-2 Infection: Applying Learnings From Real World Evidence to Real World Practice

Nancy Carteron, MD, FACR - Congress Insights Direct From Chicago: The Need-to-Knows on B Cell–Targeting in Sjögren’s Disease

Eva Diehl - Wiesenecker, MD - Rare Causes of Abdominal Pain: Differential Diagnosis of Uncommon but Diagnosable Causes in the Emergency Room

Thanai Pongdee, MD - From Diagnosis to Treatment Escalation: Improving Outcomes Across the Patient Journey in Indolent Systemic Mastocytosis

Martin Metz, MD - Bringing Chronic Spontaneous Urticaria Under Control: Available and Anticipated Strategies for Escalating Treatment

Howard Trachtman, MD - Pioneering Progress In Focal Segmental Glomerulosclerosis: Time is Ticking To Save The Nephron

Saiju Jacob, MD, DPhil, FRCP, FAAN - The Value of Disease Control in gMG: The Latest Data Evaluating Patient Needs and Treatment Outcomes as They Emerge From Helsinki

Anna Maria Geretti, MD, PhD - Understanding an Individual’s Readiness for Long-Acting Injectable Therapy

Thomas Dörner, MD - B-Cell Depletion for Autoimmune Rheumatic Diseases: Expert Perspectives of This Mechanistic Therapeutic Approach in Clinical Context

Nicholas J. Silvestri, MD, FAAN - From Established to Emerging Therapies: Expert Perspectives on the Latest Evidence Base on FcRn Inhibitors for gMG

Enrico Lopriore, MD, PhD - Are You Managing Pregnant Individuals? Then You Need to Know About Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT)

James F. Howard Jr, MD - Beyond FcRn and Complement Inhibitors: Why We Need Novel Treatment Options for Generalized Myasthenia Gravis

Mariana Castells, MD, PhD - Rare But Highly Significant: Best Practices in Recognizing and Diagnosing Systemic Mastocytosis

Pushpa Narayanaswami, MD, FAAN - Cutting Through the Congress Cacophony on Generalised Myasthenia Gravis: Expert Honing of the Latest Data

Onyema Ogbuagu, MD, FACP, FIDSA - Multidrug-Resistant HIV: Evaluating HIV Treatment Strategies as Options Narrow

Stephen Jolles, MRCP, FRCPath, PhD - The Many Faces of Primary Immunodeficiencies: Exploring the Plethora of Possibilities Impacting Patient-Integrated Care

Frank Siebenhaar, PD / Vito Sabato, MD, PhD - Optimising Outcomes in Indolent Systemic Mastocytosis: A Comprehensive Review of Best Practices Across the Patient Journey

Sharon Walmsley, MD - If the Drugs Are Working, Why Switch HIV Treatment in People Who Are Virologically Suppressed?

Jane Anderson, FRCP, PhD - Health-Related Quality of Life: What Works Best for People Living With HIV?

Xenofon Baraliakos, MD, PhD / Philip Helliwell, MD, PhD - Can the Standard of Care Be Elevated in Spondyloarthropathies? Key Learnings From Rheumacensus Initiatives in PsA and axSpA

Milan J. Anadkat, MD - Supporting Patient-Centered Care in Generalized Pustular Psoriasis: Communications Strategies to Improve Shared Decision-Making